Retinal Vein Occlusion (RVO) Treatment Market - By Condition Type (Branch, Central), Treatment Type (Corticosteroids, Anti-VEGF, Laser Therapy), Medication Type (Branded, Generics), End-user (Hospital, Ophthalmic Clinic, ASC) – Global Forecast (2024 – 2032)

Retinal Vein Occlusion Treatment Market Size

Retinal Vein Occlusion Treatment Market size was valued at USD 2.2 billion in 2023 and is estimated to grow at 5.8% CAGR from 2024 to 2032. RVO is among the most common retinal vascular diseases. The market has seen considerable growth due to the rising prevalence of diabetes and hypertension, a key risk factors of RVO driving demand for effective treatments.
 

According to the World Health Organization (WHO), around 1.28 billion adults aged 30-79 worldwide suffer from hypertension, with two-thirds living in middle- and low-income countries. Hypertension can cause occlusion of major retinal vessels, such as the central and branch retinal veins, leading to vascular occlusion and vision loss. As a result, the increasing incidence of these hypertension-related complications is expected to drive the prevalence of RVO, thereby supporting market growth. Moreover, advancements in diagnostic technologies and therapeutic options including ophthalmology drugs such as anti-VEGF drugs and corticosteroid implants are improving patient outcomes and fueling market expansion.
 

Retinal vein occlusion (RVO) is a common retinal vascular disorder characterized by the blockage of the retinal veins, leading to impaired blood flow and potential vision loss. It occurs when a blood clot forms in the retinal vein, resulting in swelling, hemorrhage, and ischemia within the retina. RVO is primarily classified into two types that include central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO), depending on the location of the blockage.
 

Retinal Vein Occlusion Treatment Market Trends

Increased funding and research activities are leading to the development of advanced therapeutic options such as novel anti-VEGF therapies and sustained-release corticosteroid implants along with other therapy interventions. These advancements tend to improve treatment efficacy and patient outcomes further fostering the market demand. Also, ongoing clinical trials and new product launches enhance market growth by expanding available treatment options and improving disease management strategies.
 

• For instance, Roche introduced new 72-week data from two global Phase III studies, BALATON (NCT04740905) and COMINO (NCT04740931), evaluating faricimab (Vabysmo) for macular edema due to BRVO and CRVO. The findings indicated that nearly 60% of participants in the BALATON trial and up to 48% in the COMINO trial were able to extend their treatment intervals to three or four months after Vabysmo administration. This significant improvement compared to the typical one to two-month intervals for existing RVO treatments resulted in reinforcing efficacious treatment options for retinal conditions causing vision loss. Such trials in pipeline is expected to spur the market growth.
   

Moreover, the growing aging population with vision complications, strategic expansions by key players, increasing approvals, and advancements in drug delivery are further boosting market demand.
 

Retinal Vein Occlusion Treatment Market Analysis

Based on the condition type, the market is categorized into branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). The CRVO segment is set to lead the market, accounting for the largest revenue of USD 1.5 billion, anticipating its dominance throughout the forecast period with a CAGR of 5.7%.
 

• CRVO occurs by the blockage of the main retinal vein, typically due to thrombosis. Its pathogenesis involves retinal vein compression and vascular endothelial damage, leading to complications like retinal neovascularization and macular edema. The complications associated with the condition emerged as the need for an effective therapy line driving the market demand.
   
• Also, the growing burden of CRVO has boosted the R&D efforts, leading to the development of targeted therapies and innovative treatment modalities specifically tailored to address the challenges, further solidifying the segment dominance in the market.
   
• For instance, 3SBio's anti-VEGF monoclonal antibody, 601A, is currently undergoing Phase I/IIa clinical trials, offering promising prospects for CRVO therapy with its potential to address the underlying mechanisms and alleviate associated symptoms. Thus, growing research efforts to cater to the need for advanced therapeutic options further solidify the segment dominance.
   

Based on treatment type, the retinal vein occlusion treatment market is classified into anti-VEGF therapy, corticosteroids, laser therapy, and other treatment types. The anti-VEGF therapy segment holds the largest market share of 67.6% in 2023 and is expected to maintain dominance throughout the analysis period.
 

• The advent of anti-VEGF therapy marked a significant breakthrough in treating RVO, including age-related macular degeneration. The studies have reported that anti-VEGF therapy tends to prevent vision loss along with sustained vision improvements lasting up to five years. Similarly, the increasing emphasis on ophthalmology drugs driven by rising awareness of retinal conditions has prompted major market players to prioritize the development and approval of innovative therapies tailored to address specific challenges, thereby expanding opportunities within the sector.
   
• For instance, in May 2024, Biocon Biologics Ltd., a subsidiary of Biocon Ltd, obtained U.S. Food and Drug Administration (US FDA) approval for Yesafili, a VEGF inhibitor biosimilar to EYLEA (aflibercept) in the U.S. Yesafili, is intended for various ophthalmology conditions including neovascular (wet AMD) age-related macular degeneration, RVO-associated macular edema, diabetic macular oedema (DME), and myopic (choroidal neovascularization) CNV. The approval marked a significant expansion of the ophthalmology therapeutics in the U.S. market.
   
• Thus, ongoing R&D efforts aimed at enhancing anti-VEGF treatments further solidify their position as the preferred choice for managing RVO, thereby driving their dominance within the market landscape.
   

Based on medication type, the retinal vein occlusion treatment market is segmented into branded and generics. In 2023, the branded segment is expected to reach USD 2.2 billion by 2032.

• Branded medications often hold a strong brand recognition, physician trust, and established efficacy profiles, which contribute to their preferential use by healthcare providers. Also, branded drugs may benefit from extensive marketing efforts and patient loyalty programs, further solidifying their market share. These factors, coupled with limited competition from generic alternatives, enable branded medications to maintain their stronghold and dominance within the market landscape.
   
• Furthermore, available of branded corticosteroids in the market will foster the segment growth. These drugs offer the advantage of addressing key components of RVO's pathophysiology, including stabilizing the blood-retina barrier and reducing vascular permeability and macular edema by inhibiting inflammatory mediators. Therefore, with increasing research on potential treatments, significant market growth is anticipated.
   

Based on the end-user, the retinal vein occlusion treatment market is segmented into hospitals, ophthalmic clinics, ambulatory surgical centers (ASCs), and academic and research institutes. The hospital segment is projected to exhibit CAGR of 5.6% during the analysis period.
 

• Hospitals are major users of retinal vein occlusion treatment for various medical procedures, including surgeries, dental treatments, and emergency care. Their consistent demand for retinal vein occlusion treatment in bulk quantities, coupled with their preference for high-quality and reliable pharmaceutical products, has contributed to the segment's dominance.
   
• Additionally, hospitals often have established procurement channels and partnerships with pharmaceutical suppliers, further solidifying their position in the market.
   

The U.S. dominated the North American retinal vein occlusion treatment market accounting for USD 858.5 million in 2023 and is anticipated to show considerable growth over the analysis period.
 

• The U.S. holds a prominent position due to the high prevalence of diabetes and hypertension, major risk factors for RVO. For instance, as per the Centers for Disease Control and Prevention (CDC), approximately 12 million individuals aged 40 and older experienced vision impairment in the U.S. Similarly, favorable reimbursement policies are anticipated to augment market expansion. In the U.S., the healthcare reimbursement framework extended coverage to approximately 84% of the population, with public (26%) or private (70%) health insurance. Thus, growing prevalence coupled with favorable reimbursement policies fuels the treatment demand.
   
• Further, the presence of key players, academic institutions, and clinical trial sites fosters advancements in RVO management and therapeutic approaches, thereby solidifying the country’s prominence in the North American market.
   

Germany exhibited a high growth potential in the European retinal vein occlusion treatment market.
 

• Germany boasts a robust healthcare infrastructure and advanced medical facilities, facilitating widespread access to RVO diagnosis and treatment in Europe. The country is renowned for its strong research capabilities coupled with the presence of research institutions and academic centers, driving innovation in RVO therapies through clinical trials and collaborative efforts further solidifying the country’s prominence in the European market.
   
• For instance, a research study featured in Nature in January 2023 assessed a novel personalized 2mg aflibercept treatment regimen for individuals with treatment for BRVO accompanied by macular edema. Such initiatives are poised to propel the market growth.
   

The Asia Pacific retinal vein occlusion treatment market is poised for rapid growth with a CAGR of 6.3% during the forecast period.
 

• The Asia Pacific region offers substantial growth potential in the market driven by factors such as the well-established healthcare infrastructure in countries like Japan, and ongoing advancements in India and China. As most countries in this region are developing economies, there is a swift adoption of innovative therapies.
   
• Moreover, with the rising prevalence of eye disorders in the Asia Pacific region, governments are prioritizing support for diagnostics and treatment, aiming to curtail disease progression and enhance early detection. These factors are poised to explore opportunities for the Asia Pacific region in the market.
   

Retinal Vein Occlusion Treatment Market Share

The competitive landscape of the market is characterized by the presence of several key players striving to address the growing demand for effective therapies. The companies are focusing on innovative RVO treatment options, including anti-VEGF drugs, corticosteroids, and surgical interventions. These companies are investing heavily in R&D to enhance treatment efficacy and expand their product portfolios. Moreover, strategic collaborations, mergers, and acquisitions are common tactics employed to strengthen market presence and gain a competitive edge.
 

Retinal Vein Occlusion Treatment Market Companies

Few of the prominent players operating in the retinal vein occlusion treatment industry include:

• Allergan, Inc.
• Aerie Pharmaceuticals Inc.
• Bayer AG
• Biocon Biologics Ltd
• Chugai Pharmaceutical Co., Ltd.
• Coherus BioSciences, Inc.
• EyePoint Pharmaceuticals Inc.
• Genentech Inc. (F. Hoffmann-La Roche Ltd.)
• Novartis AG
• Regeneron Pharmaceuticals Inc
• Samsung Bioepis Co., Ltd.
   

Retinal Vein Occlusion Treatment Industry News:

• In March 2024, Chugai Pharmaceutical Co., Ltd. secured regulatory clearance from Japan's Ministry of Health, Labour and Welfare (MHLW) for Vabysmo Intravitreal Injection 120 mg/mL, a bispecific antibody targeting anti-VEGF/anti-Ang-2, for treating macular edema linked with RVO. This approval is expected to enhance company’s outreach to untapped economies.
   
• In February 2024, Samsung Bioepis obtained approval from the Korean Ministry of Food and Drug Safety for Afilivu, a biosimilar to Regeneron's Eylea (aflibercept), marking the first approval of an aflibercept biosimilar in Korea. The approval signified an opportunity to advance accessible and affordable treatment options for RVO.
   

The retinal vein occlusion treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Condition Type

• Branch retinal vein occlusion (BRVO)
• Central retinal vein occlusion (CRVO)

Market, By Treatment Type

• Anti-VEGF therapy
• Corticosteroids
• Laser therapy
• Other treatment types

Market, By Medication Type

• Branded
• Generics

Market, By End-user

• Hospitals
• Ophthalmic clinics
• Ambulatory surgical centers (ASCs)
• Academic and research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa